Engraftment syndrome emerges as the main cause of transplant-related mortality in pediatric patients receiving autologous peripheral blood progenitor cell transplantation

Journal of Pediatric Hematology/Oncology

Volumn 26, Issue 8, 2004, Pages 492-496

  Foncillas, Maria A ^a   Diaz, Miguel A ^a   Sevilla, Julián ^a   Gonzalez Vicent, Marta ^a   Fernandez Plaza, Sandra ^a   Pérez, Antonio ^a   Madero, Luis ^a  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

Autologous peripheral blood progenitor cell transplantation; Children; Engraftment syndrome; Treatment related mortality

Indexed keywords

BUSULFAN; CARBOPLATIN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THIOTEPA;

ADOLESCENT; ADULT; AGE; ARTICLE; AUTOTRANSPLANTATION; CAUSE OF DEATH; CHILD; CHILDHOOD MORTALITY; ENGRAFTMENT SYNDROME; FEMALE; GENDER; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LEUKAPHERESIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PEDIATRICS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; REMISSION; RISK FACTOR; WHOLE BODY RADIATION;

ADOLESCENT; ANTIGENS, CD34; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FEVER; HUMANS; INCIDENCE; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; NEUROBLASTOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; RHABDOMYOSARCOMA; SARCOMA, EWING'S; SURVIVAL RATE; SYNDROME; TRANSPLANTATION, AUTOLOGOUS;

EID: 3843138530     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000130217.41531.fb     Document Type: Article

References (45)

1. Weaver CH, Schwartzberg LS, Hainsworth J, et al. Treatment-related mortality in 1000 consecutive patients receiving high dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant. 1997;19:671-678.
2. Peters WP, Ross M. Vredenburgh et al. High-dose chemotherapy and autologous bone marrow support after standard-dose therapy for high-risk primary breast cancer. J Clin Oncol. 1993;11:1132.
3. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin lymphoma. N Engl J Med. 1995;333:1540-1545.
4. Linch DC, Hancock B, Winfield D, et al. Dose intensification with autologous bone marrow transplantation in relapse and resistant Hodgkifis disease. Lancet. 1993;341:1051-1054.
5. Balduzzi A, Valsecchi MG, Silvestri D, et al. Transplant-related toxicity and mortality: an AIEOP prospective study in 636 pediatric patients transplanted for acute leukemia. Bone Marrow Transplant. 2002;29:93-100.
6. Gratwohl A, Hermans J, Baldomero H, et al. Hematopoietic precursor cell transplants in Europe: activity in 1994. Report from the EBMT. Bone Marrow Transplant. 1996;17:137-148.
7. To LB, Roberts MM, Haylock DN, et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase PBSC transplant, autologous bone marrow transplants and allogenic bone marrow transplants. Bone Marrow Transplant. 1992;9:277-284.
8. Henon PR, Liang H, Beck-Wirth G, et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplant. Bone Marrow Transplant. 1992;9:285-291.
9. Majolino I, Pearce R, Taghipour G, et al. PBSC transplant versus autologous bone marrow transplant in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation registry data. J Clin Oncol. 1997;15:509-517.
10. Subira M, Sureda A, Martro R, et al. Autologous stem cell transplant for high-risk Hodgkin's disease: improvement over time and impact of conditioning regimen. Haematologica. 2000;2:167-172.
11. Thomas ED, Blume KG, Forman SJ. Hematopoietic Cell Transplantation, 2nd ed. Malden, MA: Blackwell Science, 1999.
12. Perry AR, Rivlin MM, Goldstone AH. Bone marrow transplantation patients with life-threatening organ failure: when should treatment stop? J Clin Oncol. 1999;17:289-303.
13. Soubani AO, Miller KB, Hassoun PM, et al. Pulmonary complications of bone marrow transplant. Chest. 1996;109:1066.
14. Jain B, Floreani AA, Anderson JR, et al. Cardiopulmonary function and auto bone marrow transplant: results and predictive value for respiratory failure and mortality. Bone Marrow Transplant. 1996;17:561.
15. Kami M, Mori S, Tanikawa S, et al. Risk factors for hepatic venoocclusive disease after bone marrow transplant: analysis of 137 cases at a single institution. Bone Marrow Transplant. 1997;20:397.
16. Cox GJ, Matsui SM, Lo RS, et al. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology. 1994;107:1398.
17. Ketterer N, Sonet A, Dumontet C, et al. Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: analysis of 300 cases in a single institution. Bone Marrow Transplant. 1999;23:1309-1315.
18. Mavroudis D, Read E, Cottler-Fox M, et al. CD 34+ cell dose predicting survival, posttransplant morbidity and rate of hematological recovery after allogeneic marrow transplant for hematological malignancies. Blood. 1996;98:3223.
19. Diaz MA, Alegre A, Villa M, et al. Collection and transplantation of peripheral blood progenitor cells mobilized by G-CSF alone in children with malignancy. Br J Haematol. 1996;94:148.
20. Madero L, Gonzalez Vicent M, Molina J, et al. Use of concurrent G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells in children with malignant disease. Bone Marrow Transplant. 2000;26:365-369.
21. Sevilla J, Gonzalez Vicent M, Madero L, et al. Granulocyte colony-stimulating factor alone at 12 μg/kg twice a day for four days for peripheral blood progenitor cell priming in pediatric patients. Bone Marrow Transplant. 2002;30:417-420.
22. Diaz MA, Alegre A, Benito A, et al. PBSC collection by large volume leukapheresis in low-weight children. J Hematolther. 2000;7:63-68.
23. Alegre A, Diaz MA, Madero L, et al. Large-volume leukapheresis for PBSC collection in children: a simplified single apheresis approach. Bone Marrow Transplant. 1996;17:923-927.
24. Lee CK, Gringrich RD, Holh RJ, et al. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation. Bone Marrow Transplant. 1995;16:175-182.
25. Madero L, Vicent MG, Sevilla J, et al. Engraftment syndrome in children undergoing autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant. 2002;30:355-358.
26. Stockerl-Goldstein KE, Horning SJ, Negrin RS, et al. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 1996;2:76-85.
27. Korbling M, Holle R, Haas R, et al. Autologous blood stem cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site. J Clin Oncol. 1990;8:978.
28. Sheridan WP, Begley CJ, Juttner CA, et al. Effect of peripheral blood progenitor cell mobilized by G-CSF on platelet recovery after high-dose chemotherapy. Lancet. 1992;339:640.
29. Weaver C, Schwatzberg L, Li W, et al. High-dose chemotherapy and peripheral blood progenitor cell transplantation for the treatment of Hodgkin's disease. Bone Marrow Transplant. 1996;17:715.
30. Tarella C, Gavarotti P, Caracciolo D, et al. Haematological support of high dose sequential chemotherapy: clinical evidence for reduction of toxicity and high response rates in poor risk lymphoma. Ann Oncol. 1995;6(Suppl.4):3-8.
31. Long GD, Chao NJ, Hu WW, et al. High-dose etoposide based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma. Cancer. 1996;78:2502-2509.
32. Kruger W, Russmann B, Kroger N, et al. Early infections in patients undergoing bone marrow or blood stem cell transplant: a 7-year single-centre investigation of 409 cases. Bone Marrow Transplant. 1999;23:589-597.
33. Weaver CH, Appelbaum FR, Petersen FB, et al. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplant in patients with lymphoid malignancies. J Clin Oncol. 1993;11:1329-1335.
34. Chopra R, McMillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin disease. A single-center study in 155 patients. Blood. 1993;81:1137-1145.
35. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol. 1990;17:10-13.
36. Hovi L, Saarinen-Pihkala, Vettenranta K, et al. Invasive fungal infections in pediatric bone marrow transplant recipient: single-center experience of 10 years. Bone Marrow Transplant. 2000;26:999-1004.
37. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease: liver toxicity syndrome after bone marrow transplant. Bone Marrow Transplant. 1992;10:197.
38. Kroger N, Zabalina T, Sonnenberg S, et al. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with AML. Bone Marrow Transplant. 2000;26:711.
39. Horn B, Reiss U, Matthay K, et al. Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma. Bone Marrow Transplant. 2002;29:409.
40. Fisher DC, Vredenburgh JJ, Petro L, et al. Reduced mortality following bone marrow transplant for breast cancer with addition of peripheral blood progenitors due to a marked reduction in veno-occlusive disease of the liver. Bone Marrow Transplant. 1998;21:117.
41. Diaz MA, Gonzalez Vicent M, Prudencio M, et al. Predicting factors for admission to an intensive care unit and clinical outcome in pediatric patients receiving hematopoietic stem cell transplantation. Haematologica. 2002;87:292-298.
42. Edenfield WJ, Moores LK, Goodwin G, et al. An engraftment syndrome in autologous stem cell transplantation related to mononuclear cell dose. Bone Marrow Transplant. 2000;25:405-409.
43. Ravoet C, Feremans W, Husson B, et al. Clinical evidence for engraftment syndrome associated with early and steep neutrophil recovery after autologous blood stem cell transplantation. Bone Marrow Transplant. 1996;18:943-947.
44. Testa U, Martucci R, Rutella S, et al. Autologous stem cell transplantation: release of early- and late-acting growth factors relates with hematopoietic ablation and recovery. Blood. 1994;84:3532-3539.
45. Steffen M, Durken M, Pichlmeier U, et al. Serum interleukin-6 levels during bone marrow transplantation: impact on transplant-related toxicity and engraftment. Bone Marrow Transplant. 1996;18:301-307.